968-49-0

Usage

Uses

Used in Pharmaceutical Industry:
19-ALDOANDROSTENEDIONE is used as a pharmaceutical intermediate for the synthesis of various steroidal drugs. It serves as a key building block in the production of anabolic steroids, corticosteroids, and other hormone-related medications due to its unique chemical structure and properties.
Used in Research and Development:
19-ALDOANDROSTENEDIONE is utilized as a research compound in the field of endocrinology and biochemistry. It aids scientists in understanding the mechanisms of steroid hormone synthesis, metabolism, and their effects on the human body.
Used in Sports Nutrition:
19-ALDOANDROSTENEDIONE is used as a dietary supplement in sports nutrition to enhance athletic performance. It is believed to increase testosterone levels, improve muscle mass, and boost strength, although its efficacy and safety are subjects of ongoing research and debate.
Used in Hormone Replacement Therapy:
19-ALDOANDROSTENEDIONE is employed as a precursor in the synthesis of hormones used in hormone replacement therapy. It contributes to the production of hormones that help maintain healthy bodily functions and alleviate symptoms associated with hormonal imbalances.

InChI:InChI=1/C19H24O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10-11,14-16H,2-9H2,1H3/t14-,15-,16-,18-,19+/m0/s1

Upstream product

• 63-05-8 Androstenedione 
• 510-64-5 19-hydroxy-4-androstene-3,17-dione 

Downstream Products

• 64-18-6 formic acid 
• 53-16-7 Estrone 
• 734-32-7 19-norandrost-4-ene-3,17-dione 
• 5189-96-8 10β-hydroxy-19-norandrost-4-ene-3,17-dione 
• 510-64-5 19-hydroxy-4-androstene-3,17-dione 
• 4757-95-3 androst-4-ene-3,17-dion-19-oic acid 
• 2135-57-1 10β-Hydroperoxy-Δ⁴-oestren-3,17-dion 
• 22256-03-7 4-Androsten-19-oic-3,17-dione methyl ester 
• 734-32-7 estra-4-ene-3,17-dione 
• 68-22-4 norethisterone 
• 2863-88-9 3-ethoxy-19-nor-3,5-androstadiene-17-one 
• 3962-66-1 estra-5⁽¹⁰⁾-en-3,17-dione 
• 160617-57-2 (19R)-19-hydroxy-5β,19-cycloandrostane-3,17-dione 
• 160617-58-3 (19S)-19-hydroxy-5β,19-cycloandrostane-3,17-dione 

Relevant academic research and scientific papers

Kinetic solvent isotope effect in steady-state turnover by CYP19A1 suggests involvement of Compound 1 for both hydroxylation and aromatization steps

CYP19A1, or human aromatase catalyzes the conversion of androgens to estrogens in a three-step reaction through the formation of 19-hydroxy and 19-aldehyde intermediates. While the first two steps of hydroxylation are thought to proceed through a high-valent iron-oxo species, controversy exists surrounding the identity of the reaction intermediate that catalyzes the lyase and aromatization reaction. We investigated the kinetic isotope effect on the steady-state turnover of Nanodisc-incorporated human CYP19A1 to explore the mechanisms of this reaction. Our experiments reveal a significant (～2.5) kinetic solvent isotope effect for the C10-C19 lyase reaction, similar to that of the first two hydroxylation steps (2.7 and 1.2). These data implicate the involvement of Compound 1 as a reactive intermediate in the final aromatization step of CYP19A1.

Chloroiron(III)-5,10,15,20-tetraarylporphinate/N-methylimidazole catalyzed oxidation of androst-4-en-3,17-dione by cumene hydroperoxide

The oxidation of androst-4-en-3,17-dione with cumene hydroperoxide, catalyzed by chloroiron(III)-5,10,15,20-tetraarylporphinate/N-methyl-imidazole systems, was studied under different reaction conditions. The chloroiron(III)-5,10,15,20-tetra(2,6-dichlorophenyl)porphinate/N-methy limidazole system in dichloromethane was found to be the most effective system for the aromatization of the A ring of androst-4-en-3,17-dione.